StockData
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC (ADAPY) stock

ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2025, quarter ended Jun 30, 2025Last filing: 10-Q on Aug 13, 2025Score 3/30
$0.04+0.00 (+9.38%)

Close on Oct 19, 2026Market cap $55.46MP/E –Yield –

Adaptimmune Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Adaptimmune Therapeutics's operating income for the twelve months ending Jun 30, 2025 was -$164.22M. For fiscal 2024 it was -$68.76M. The highest annual figure on record is -$11.52M in fiscal 2014.

Annual operating income

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$68.76M–
FY2023Dec 31, 2023-$139.74M–
FY2022Dec 31, 2022-$163.97M–
FY2021Dec 31, 2021-$162.25M–
FY2020Dec 31, 2020-$133.41M–
FY2019Dec 31, 2019-$139.77M–
FY2018Dec 31, 2018-$82.37M–
FY2017Dec 31, 2017-$80.66M–
FY2015Jun 30, 2015-$24.64M–
FY2014Jun 30, 2014-$11.52M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2025CQ2 2025Jun 30, 2025-$30.29M-144.1%
Q1 FY2025CQ1 2025Mar 31, 2025-$45.73M–
Q4 FY2024CQ4 2024Dec 31, 2024-$73.52M–
Q3 FY2024CQ3 2024Sep 30, 2024-$14.68M–
Q2 FY2024CQ2 2024Jun 30, 2024$68.70M–
Q1 FY2024CQ1 2024Mar 31, 2024-$49.26M-3074.7%
Q4 FY2023CQ4 2023Dec 31, 2023-$49.86M–
Q3 FY2023CQ3 2023Sep 30, 2023-$46.63M–
Q2 FY2023CQ2 2023Jun 30, 2023-$44.91M–
Q1 FY2023CQ1 2023Mar 31, 2023$1.66M–
Q4 FY2022CQ4 2022Dec 31, 2022-$27.24M–
Q3 FY2022CQ3 2022Sep 30, 2022-$42.99M–
Q2 FY2022CQ2 2022Jun 30, 2022-$43.75M–
Q1 FY2022CQ1 2022Mar 31, 2022-$49.98M–
Q4 FY2021CQ4 2021Dec 31, 2021-$42.86M–
Q3 FY2021CQ3 2021Sep 30, 2021-$42.18M–
Q2 FY2021CQ2 2021Jun 30, 2021-$39.31M–
Q1 FY2021CQ1 2021Mar 31, 2021-$37.89M–
Q4 FY2020CQ4 2020Dec 31, 2020-$37.51M–
Q3 FY2020CQ3 2020Sep 30, 2020-$35.88M–
Q2 FY2020CQ2 2020Jun 30, 2020-$30.25M–
Q1 FY2020CQ1 2020Mar 31, 2020-$29.76M–
Q4 FY2019CQ4 2019Dec 31, 2019-$30.36M–
Q3 FY2019CQ3 2019Sep 30, 2019-$40.12M-671.7%
Q2 FY2019CQ2 2019Jun 30, 2019-$35.50M–
Q1 FY2019CQ1 2019Mar 31, 2019-$33.79M–
Q4 FY2018CQ4 2018Dec 31, 2018-$32.11M–
Q3 FY2018CQ3 2018Sep 30, 2018$7.02M–
Q2 FY2018CQ2 2018Jun 30, 2018-$28.88M–
Q1 FY2018CQ1 2018Mar 31, 2018-$28.74M–
Q4 FY2017CQ4 2017Dec 31, 2017-$29.70M–
Q3 FY2017CQ3 2017Sep 30, 2017-$4.96M–
Q2 FY2017CQ2 2017Jun 30, 2017-$23.78M–
Q1 FY2017CQ1 2017Mar 31, 2017-$22.22M–
Q4 FY2015CQ2 2015Jun 30, 2015-$11.11M–
Q3 FY2015CQ1 2015Mar 31, 2015-$5.61M–

More Adaptimmune Therapeutics figures

See a number that looks wrong?